Ocugen Inc. [NASDAQ: OCGN] closed the trading session at $0.31 on 10/21/20. The day’s price range saw the stock hit a low of $0.3101, while the highest price level was $0.3235. The company report on October 16, 2020 that Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen.
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.
Ocugen management, including Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Sanjay Subramanian, CFO, Dr. Mohamed Genead, Acting CMO and Chair of the Scientific Advisory Board, and Dr. Mark Pennesi, Scientific Advisory Board Member, will discuss Ocugen’s lead program, OCU400 (AAV-NR2E3), a modifier gene therapy indicated for retinal degeneration disorders. In addition, they will provide highlights from the clinical, histological, and functional outcomes as published in Nature Gene Therapy evaluating AAV-NR2e3. They will also provide retina and disease backgrounds of members of the Retina Scientific Advisory Board. Lastly, they will provide an update on their goal of initiating two clinical trials in 2021 for OCU400 and expanding into four clinical trials in 2022 with OCU410 (AAV-RORA) for the treatment of dry age-related macular degeneration and OCU200, a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related Macular Degeneration.
The stocks have a year to date performance of -39.42 percent and weekly performance of -5.69 percent. The stock has been moved at -2.14 percent over the last six months. The stock has performed -5.69 percent around the most recent 30 days and changed 11.03 percent over the most recent 3-months.
If compared to the average trading volume of 31.31M shares, OCGN reached to a volume of 2934460 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Ocugen Inc. [OCGN]:
The Average True Range (ATR) for Ocugen Inc. is set at 0.02, with the Price to Sales ratio for OCGN stock in the period of the last 12 months amounting to 1026.74. The Price to Book ratio for the last quarter was 1.75, with the Price to Cash per share for the same quarter was set at 0.11.
OCGN stock trade performance evaluation
Ocugen Inc. [OCGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.69. With this latest performance, OCGN shares dropped by -5.69% in over the last four-week period, additionally sinking by -2.14% over the last 6 months – not to mention a drop of -84.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCGN stock in for the last two-week period is set at 43.19, with the RSI for the last a single of trading hit 42.57, and the three-weeks RSI is set at 45.26 for Ocugen Inc. [OCGN]. The present Moving Average for the last 50 days of trading for this stock 0.3681, while it was recorded at 0.3186 for the last single week of trading, and 0.3839 for the last 200 days.
Ocugen Inc. [OCGN]: An insightful look at the core fundamentals
Ocugen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.30 and a Current Ratio set at 3.30.
Earnings per share (EPS) analysis for Ocugen Inc. [OCGN] stock
With the latest financial reports released by the company, Ocugen Inc. posted -4.8/share EPS, while the average EPS was predicted by analysts to be reported at -0.6/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -700.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OCGN.
Ocugen Inc. [OCGN]: Insider Ownership positions
There are presently around $1 million, or 7.40% of OCGN stock, in the hands of institutional investors. The top three institutional holders of OCGN stocks are: BLACKROCK INC. with ownership of 645,985, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; CITADEL ADVISORS LLC, holding 465,972 shares of the stock with an approximate value of $0.15 million in OCGN stocks shares; and VANGUARD GROUP INC, currently with $0.1 million in OCGN stock with ownership of nearly 0% of the company’s market capitalization.
10 institutional holders increased their position in Ocugen Inc. [NASDAQ:OCGN] by around 881,378 shares. Additionally, 6 investors decreased positions by around 1,029,549 shares, while 6 investors held positions by with 641,591 shares. The mentioned changes placed institutional holdings at 2,552,518 shares, according to the latest SEC report filing. OCGN stock had 6 new institutional investments in for a total of 370,770 shares, while 3 institutional investors sold positions of 186,530 shares during the same period.